vs
WM TECHNOLOGY, INC.（MAPS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
WM TECHNOLOGY, INC.的季度营收约是REGENXBIO Inc.的1.4倍（$43.1M vs $30.3M），WM TECHNOLOGY, INC.净利率更高（-8.3% vs -221.3%，领先213.0%），REGENXBIO Inc.同比增速更快（43.0% vs -9.7%），WM TECHNOLOGY, INC.自由现金流更多（$-280.0K vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -1.5%）
WM娱乐是韩国一家娱乐经纪公司，由前歌手李元敏创立于2008年，核心业务为艺人经纪管理，知名女团Oh My Girl便由该公司运营管理，2021年4月7日，WM娱乐被RBW公司收购。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
MAPS vs RGNX — 直观对比
营收规模更大
MAPS
是对方的1.4倍
$30.3M
营收增速更快
RGNX
高出52.7%
-9.7%
净利率更高
MAPS
高出213.0%
-221.3%
自由现金流更多
MAPS
多$52.5M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-1.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $43.1M | $30.3M |
| 净利润 | $-3.6M | $-67.1M |
| 毛利率 | 94.9% | — |
| 营业利润率 | -13.5% | -190.0% |
| 净利率 | -8.3% | -221.3% |
| 营收同比 | -9.7% | 43.0% |
| 净利润同比 | -251.9% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MAPSRGNX
| Q4 25 | $43.1M | $30.3M | ||
| Q3 25 | $42.2M | $29.7M | ||
| Q2 25 | $44.8M | $21.4M | ||
| Q1 25 | $44.6M | $89.0M | ||
| Q4 24 | $47.7M | $21.2M | ||
| Q3 24 | $46.6M | $24.2M | ||
| Q2 24 | $45.9M | $22.3M | ||
| Q1 24 | $44.4M | $15.6M |
净利润MAPSRGNX
| Q4 25 | $-3.6M | $-67.1M | ||
| Q3 25 | $2.5M | $-61.9M | ||
| Q2 25 | $1.4M | $-70.9M | ||
| Q1 25 | $1.6M | $6.1M | ||
| Q4 24 | $2.4M | $-51.2M | ||
| Q3 24 | $3.3M | $-59.6M | ||
| Q2 24 | $716.0K | $-53.0M | ||
| Q1 24 | $1.2M | $-63.3M |
毛利率MAPSRGNX
| Q4 25 | 94.9% | — | ||
| Q3 25 | 95.0% | — | ||
| Q2 25 | 94.9% | — | ||
| Q1 25 | 95.0% | — | ||
| Q4 24 | 95.2% | 70.2% | ||
| Q3 24 | 95.3% | 48.8% | ||
| Q2 24 | 95.1% | 52.5% | ||
| Q1 24 | 94.8% | 72.6% |
营业利润率MAPSRGNX
| Q4 25 | -13.5% | -190.0% | ||
| Q3 25 | 4.6% | -176.3% | ||
| Q2 25 | 4.4% | -296.3% | ||
| Q1 25 | 5.9% | 13.6% | ||
| Q4 24 | 9.6% | -242.1% | ||
| Q3 24 | 11.2% | -256.6% | ||
| Q2 24 | 2.7% | -251.3% | ||
| Q1 24 | 8.5% | -408.8% |
净利率MAPSRGNX
| Q4 25 | -8.3% | -221.3% | ||
| Q3 25 | 5.8% | -208.3% | ||
| Q2 25 | 3.2% | -331.8% | ||
| Q1 25 | 3.7% | 6.8% | ||
| Q4 24 | 4.9% | -241.3% | ||
| Q3 24 | 7.2% | -246.3% | ||
| Q2 24 | 1.6% | -237.7% | ||
| Q1 24 | 2.8% | -405.4% |
每股收益（稀释后）MAPSRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | $0.02 | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | $0.01 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $57.2M | $102.7M |
| 总资产 | $190.7M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MAPSRGNX
| Q4 25 | $62.4M | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | $52.0M | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益MAPSRGNX
| Q4 25 | $57.2M | $102.7M | ||
| Q3 25 | $56.9M | $161.5M | ||
| Q2 25 | $52.7M | $213.7M | ||
| Q1 25 | $48.5M | $274.2M | ||
| Q4 24 | $36.1M | $259.7M | ||
| Q3 24 | $29.5M | $301.4M | ||
| Q2 24 | $24.5M | $348.3M | ||
| Q1 24 | $20.8M | $390.7M |
总资产MAPSRGNX
| Q4 25 | $190.7M | $453.0M | ||
| Q3 25 | $192.9M | $525.2M | ||
| Q2 25 | $188.1M | $581.0M | ||
| Q1 25 | $183.8M | $490.9M | ||
| Q4 24 | $181.9M | $466.0M | ||
| Q3 24 | $173.6M | $519.1M | ||
| Q2 24 | $168.0M | $569.4M | ||
| Q1 24 | $165.8M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-280.0K | $-52.8M |
| 自由现金流率自由现金流/营收 | -0.7% | -174.0% |
| 资本支出强度资本支出/营收 | 7.7% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $13.5M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流MAPSRGNX
| Q4 25 | $3.0M | $-52.3M | ||
| Q3 25 | $6.4M | $-56.0M | ||
| Q2 25 | $11.1M | $-49.3M | ||
| Q1 25 | $5.7M | $33.6M | ||
| Q4 24 | $9.4M | $-31.6M | ||
| Q3 24 | $7.2M | $-40.5M | ||
| Q2 24 | $12.7M | $-45.5M | ||
| Q1 24 | $7.4M | $-55.5M |
自由现金流MAPSRGNX
| Q4 25 | $-280.0K | $-52.8M | ||
| Q3 25 | $3.6M | $-56.5M | ||
| Q2 25 | $8.2M | $-49.7M | ||
| Q1 25 | $2.0M | $32.6M | ||
| Q4 24 | $7.3M | $-32.7M | ||
| Q3 24 | $4.9M | $-40.9M | ||
| Q2 24 | $10.1M | $-46.0M | ||
| Q1 24 | $2.9M | $-56.0M |
自由现金流率MAPSRGNX
| Q4 25 | -0.7% | -174.0% | ||
| Q3 25 | 8.4% | -189.9% | ||
| Q2 25 | 18.3% | -232.8% | ||
| Q1 25 | 4.5% | 36.6% | ||
| Q4 24 | 15.2% | -154.2% | ||
| Q3 24 | 10.4% | -168.9% | ||
| Q2 24 | 21.9% | -206.2% | ||
| Q1 24 | 6.4% | -358.5% |
资本支出强度MAPSRGNX
| Q4 25 | 7.7% | 1.7% | ||
| Q3 25 | 6.8% | 1.7% | ||
| Q2 25 | 6.3% | 1.8% | ||
| Q1 25 | 8.2% | 1.2% | ||
| Q4 24 | 4.5% | 5.1% | ||
| Q3 24 | 5.1% | 1.3% | ||
| Q2 24 | 5.7% | 2.1% | ||
| Q1 24 | 10.2% | 3.6% |
现金转化率MAPSRGNX
| Q4 25 | — | — | ||
| Q3 25 | 2.61× | — | ||
| Q2 25 | 7.75× | — | ||
| Q1 25 | 3.44× | 5.53× | ||
| Q4 24 | 4.00× | — | ||
| Q3 24 | 2.17× | — | ||
| Q2 24 | 17.67× | — | ||
| Q1 24 | 5.97× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAPS
| Services | $39.5M | 92% |
| Other | $3.6M | 8% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
